Search for Clinical Trial Results

Neurofibromatosis Type 2 - 25 Studies Found
Status | Study |
Recruiting |
Study Name: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Condition:
Date: 2016-10-13 Interventions: Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot |
Completed |
Study Name: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Condition:
Date: 2014-03-26 Interventions: Drug: Endostatin Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Cours |
Recruiting |
Study Name: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Condition:
Date: 2014-04-29 Interventions: Drug: Axitinib Other Name: Inlyta |
Completed |
Study Name: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Condition: Neurofibromatosis Type II Date: 2011-08-17 Interventions: Drug: Everolimus (RAD001) , Afinitor® Everolimus will be provided by Novartis. Everolimus is formul |
Suspended |
Study Name: PTC299 for Treatment of Neurofibromatosis Type 2 Condition: Neurofibromatosis 2 Date: 2009-05-28 Interventions: Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until t |
Recruiting |
Study Name: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Condition:
Date: 2011-04-21 Interventions: Drug: RAD001, everolimus Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily |
Completed |
Study Name: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Condition:
Date: 2010-09-01 Interventions:
|
Active, not recruiting |
Study Name: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Condition:
Interventions: Drug: Bevacizumab Treatment will be administered on an out |
No longer available |
Study Name: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients Condition:
|
Completed |
Study Name: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Condition: Neurofibromatosis 2 Date: 2011-11-30 Interventions: Drug: RAD001 10 mg per os / day or 05mg per os / day with 12 month |